Designing new therapeutic options for heart disease
CardioMech is a Norwegian based company focused on providing a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve.
We will prioritize treating high risk patients suffering from severe symptomatic degenerative mitral regurgitation due to prolapse or flail.
CardioMech estimates a prevalence of 440,000 patients in the USA and Europe. A $6 billion market opportunity.
CardioMech's Nikolai Hiorth won the Young Investigator Award at the International Society for Medical Innovation and Technology Congress in Shanghai, China, 2014.